We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| BioMarin Pharmaceutical Inc | NASDAQ:BMRN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.80 | -2.15% | 82.00 | 80.55 | 105.00 | 84.80 | 82.32 | 84.80 | 1,632,894 | 05:00:10 |
From May 2019 to May 2024
DOW JONES NEWSWIRES
BioMarin Pharmaceutical Inc. (BMRN) will purchase an Irish biologics manufacturing facility from Pfizer Inc. (PFE) for $48.5 million to accommodate its growing portfolio of biopharmaceuticals.
The company said the acquisition price of the plant, which was completed in 2009, represents roughly one-fifth the cost of building a new plant.
"We believe that additional manufacturing capabilities beyond our current resources will be needed to support anticipated peak sales for GALNS, PEG-PAL for PKU, BMN 701 for Pompe disease, BMN 111 for achondroplasia, if they continue to progress to approval, and our other preclinical programs," said BioMarin Chief Executive Jean-Jacques Bienaime.
In April, BioMarin swung to a first-quarter loss amid higher income and depreciation expenses.
Shares slipped 1.6% to $25.30 in recent trading. Year to date, the stock is down 6%.
-By Mia Lamar, Dow Jones Newswires; 212-416-3207; mia.lamar@dowjones.com
1 Year BioMarin Pharmaceutical Chart |
1 Month BioMarin Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
